Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLUID: Ranibizumab Regimens in Wet AMD
NCT01972789Phase 4Completed
- Sponsor
- Novartis
- Start
- Oct 2013
- Primary completion
- Feb 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in exudative macular degeneration, sponsored by Novartis. Started Oct 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT01972789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01972789.